You are here: Industry Insights > Codexis

News List

Codexis and Takeda Expand Strategic Collaboration and License Agreement to Discover Additional Gene Therapy for a Fourth Rare Genetic Disorder firstwordpharma
June 11, 2021
Codexis, Inc.,today announced the expansion of its strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited for the research and development of an additional gene therapy for a lysosomal storage disorder bringing
Codexis Signs Strategic Collaboration, License Agreement with Takeda americanpharmaceuticalreview
March 27, 2020
Codexis has announced the signing of a strategic collaboration and license agreement with Takeda Pharmaceutical for the research and development of novel gene therapies ...
Takeda partners with Codexis on gene therapies for rare diseases pharmaceutical-technology
March 25, 2020
Takeda Pharmaceutical has signed a strategic collaboration and licence agreement with biotherapeutics developer Codexis to research and create gene therapies for rare disorders.
Codexis, Takeda Sign Gene Therapy Collaboration contractpharma
March 25, 2020
Partnership to leverage Codexis’ protein engineering platform to advance novel gene therapies for rare genetic disorders。
Codexis Names SVP, and CFO contractpharma
August 09, 2019
Taylor to succeed Sangster, responsible for managing all aspects of financial, accounting, investor relations, and corporate administrative functions.
Codexis, Novartis Ink Tech Transfer and License Agreement contractpharma
May 16, 2019
Novartis to leverage CodeEvolver protein engineering platform technology develop performance enzymes for use in manufacturing.
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114 firstwordpharma
July 10, 2018
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114